In the past decade, activated PPARβ/δ was considered to have no effect on weight loss in the treatment of obesity, but it deceased plasma levels of TG, LDL cholesterol and free fatty acids, and dyslipidemia [58]. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.